Press Releases


DateTitle 
5/16/19
- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life - New Long-Term Data from the KINECT 4 Study Highlight the Overall Effect of INGREZZA® (valbenazine) Treatment on Abnormal Movements in Patients with Tardive Dyskinesia SAN
5/7/19
Live Audio Webcast will be on May 14, 2019 SAN DIEGO , May 7, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, May 14, 2019 , in Las Vegas .
5/6/19
- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients - New Survey Results Show that Almost 60% of People Taking Antipsychotics
5/5/19
- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease - Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with
5/5/19
- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer - Data Analysis from the BIPARK-1 and BIPARK-2 Phase III Studies Highlighted as an Oral Presentation at the 2019 American Academy of Neurology Annual Meeting SAN DIEGO
4/30/19
- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders - Analysis of Phase III Studies Demonstrates Treatment with Opicapone Results in Improvements in ON-time Without
4/29/19
INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx Opicapone New Drug Application Submission Remains on Track for Q2 2019 Neurocrine Biosciences Plans to Meet with FDA to Discuss Registration Program for Congenital Adrenal Hyperplasia in Q3 2019
4/8/19
Conference Call and Webcast Scheduled for Monday, April 29 SAN DIEGO , April 8, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 29, 2019 .
3/28/19
SAN DIEGO and CAMBRIDGE, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for
3/12/19
- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept - Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Pediatric Patients with Congenital Adrenal
3/5/19
SAN DIEGO , March 5, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences: Cowen 39 th Annual Health
2/5/19
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA® (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately 71,500 TRx Congenital Adrenal Hyperplasia Phase II Study Initial Results Expected in Q1 2019
1/29/19
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s disease, VY-FXN01
1/16/19
INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis Patients Treated with INGREZZA Able to Remain on Existing Psychiatric Medications SAN DIEGO , Jan. 16, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc.
1/15/19
Conference Call and Webcast Scheduled for Tuesday, February 5 SAN DIEGO , Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019 .
1/6/19
- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2018 Net Product Sales of Approximately $409 Million with Approximately 71,500 TRx SAN DIEGO , Jan.
1/2/19
Live Audio Webcast will be on January 7, 2019 SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 37 th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT ( 5:30 p.m. ET ) on Monday, Jan. 7, 2019 , in San Francisco .